Belfast-based Peter Keeling, CEO, and Founder of Diaceutics – the originator of the world's first diagnostic network for precision medicine. Having floated on the AIM market of the London Stock Exchange last year, Diaceutics is firmly committed to addressing the most pronounced issues hindering the traditional cancer testing landscape. Peter has driven Diaceutics to become a leader in innovative solutions that enable Pharma to leverage diagnostic testing globally. With over 30 years in international healthcare, Peter is a thought leader in precision medicine commercialization, a respected speaker at industry events and has published widely. Peter has also spent two extended periods in applied industrial research, including a year at MITís Pharmaceutical Program. The problem is a lack of collaboration between precision medicine stakeholders. It led to a broken testing ecosystem where only 50% of eligible patients in oncology getting access to the right treatment. The Diaceutics' Network solution has been purpose-built to solve the broken testing ecosystem by enabling the industry-wide collaboration needed to get every patient the treatment they deserve I wanted to learn more about the company's story, how they are leveraging technology, and insights from their precision medicine readiness report. The second Report in their Axis for Change series analyzes the broken diagnostic testing ecosystem impeding the delivery of precision medicines today and recommends a collaborative industry solution. Peter also reveals that The Non-Small Cell Lung Cancer (NSCLC) testing market will expand to $3.6 billion in the United States by 2025 – up considerably from just $125 million today. But currently, only half of the patients with advanced NSCLC are receiving the right drug.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related